VALEANT PHARMACEUTICALS INTL INC T.VRX

2012 VALEANT $56.00 with a B1 rating from Moody

[johnnywick]

2012 Valeant was trading at $56.00 with a B1 rating from Moody
Total 2012 revenue was $3.55 billion

Now Valeant have close to 3X more revenue than 2012 and the rating is pretty much the same.. on top of that our debt level will soon get cut in half. We have tons of new drugs approval in 2017 and more fda approval in 2018.  As you can see, Valeant revenue sales already going back up ... and within 1 to 2 yrs timeframe, VRX stock price will be back above 3 digits again.

Valeant is a much better company now than it was in 2012.

( 2012 ) VRX share price was $56.00

( 2018 ) VRX will be a lot higher than $56.00

[johnnywick]

don't be a fool this company valeant going to be $100.00 again in the near future debt talk / moody junk rating.. they're meaningless focus on what's already out of the pipeline and what other new drugs coming out of the pipeline.. never short a stock when their old drugs sales are rebounding and their new drugs sales accelerating.. Valeant easy double from here in 2018

[joeybats63]

Yeah but you have to explain the whole story. In 2015 the stock hit $335 but vanquished because of bad investing, insider trading, and product gauging. Then the companty gets into a $32 billion hole and recently paid off $6 billion. Plus the company refinanced to have the next 2 years free from paying debt. Papa the CEO has done a great job and has gone back to organics but the company isn't